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ABSTRACT
Poor medication adherence among persons diagnosed
with a severe and persistent mental illness causes
repeated psychotic episodes that lead to

rehospitalization, incarceration, adverse side effects,
and suicide. This research study is exploratory in nature
and utilized a methodology that elucidates the reasons

for psychotropic nonadherence from the client's
perspective. This study included 16 participants

diagnosed with a severe and persistent mental illness,

who are currently receiving case management and
psychiatric services from a community-based mental health
agency. The survey instrument is a 10-item, one-to-one,

semi-structured interview. Open-ended questions were
designed to generate possible barriers to psychotropic

adherence. At the conclusion of this study, researchers
identified themes from the participants' responses. Many
of the same themes stated in current research were

identified in the responses (i.e., side effects,
relationship with mental health professionals, and
insight) . The response's derived from this study can be

used to-create new treatment interventions and recovery
plans.
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CHAPTER ONE
INTRODUCTION

This chapter provides an overview of the problems

persons diagnosed with a severe and persistent mental
illness experience as a result of nonadherence to

psychotropic medication, the importance of studying
nonadherence, the role of the mental health social
worker, the methodology employed for this study, and its
potential contributions to the field of social work.

Problem Statement
According to a study by the World Health

Organization "mental illness (including depression,
bipolar disorder, and schizophrenia) is the leading cause

of disability worldwide, accounting for 25 percent of all
disabilities across major industrialized countries" (New

Freedom Commission on Mental Health, SMA-03-3832, 2003).
Unfortunately, most people do not seek mental health

treatment, which can lead to debilitating symptoms and
diminished quality of life (Bond, Drake, Mueser, &

Latimer, 2001). Medication nonadherence in individuals

with a severe and persistent mental illness (SPMI) is
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highly correlated with increased levels of symptomatology

leading to relapse, adverse side effects,
rehospitalization, incarceration, and suicide (Balon,
2002; Hewitt & Birchwood, 2002; Kopelowicz & Lieberman,
2003; Pinikahana, Happell, Taylor, & Keks, 2002; Trauer &

Sacks, 1998; Wykes & Gournay, 2002).
In the U.S. alone, 22-23 percent of the adult

population, 44 million people has a mental illness, of

which, 2.6 percent-has a SPMI (U.S. Department of Health

and Human Services [USDHHS], 1999). Furthermore, studies

indicate that more than 50 percent of individuals taking

psychotropics are nonadherent and at risk of relapse
(Byrne, Deane, Lambert & Coombs, 2004; Dixon, Weiden,

Torres & Lehman, 1997; Dodler, Lacro, Dunn & Jeste, 2002;
Hogarty & Ulrich, 1998; Hughes & Hill, 1997).

Wykes and Gournay (2002) suggest that persons with a

SPMI considered to be medication nonadherent have not

taken their medication regimen as prescribed by a mental
health professional. Although several attempts have been

made to measure medication adherence through blood/urine

tests, psychiatric assessments, pill counts, and
self-reports, none of their methods were effective (Wykes

& Gournay, 2002).
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A study by Trauer and Sacks (1998) compared

judgments concerning the medication adherence between the

individual with the SPMI, the case manager, and the
doctors, and found that "12.5 percent, or one in eight,

of the clients thought by both clinicians to be
compliant, rated themselves as noncompliant."

According to Hayward and Chan (1995), "...adherence
to these drug regimes offers hope for a greatly increased
quality of life for the long term mentally ill as well as

an enormous saving of public money." Despite the hope
pharmacotherapy brings to individuals with SPMI in the
recovery process, many individuals continue to be

nonadherent.

Under the rights-driven model, one of two approaches
to treatment refusal, clients have the right to refuse
medication regardless of the benefit (Kasper, Hoge,

Feucht-Haviar, Cortina, & Cohen, 1997).

Micro/Macro Policy.
The National Association of Social Workers (NASW)
Code of Ethics (1999) delineates ethical principles which

guide both micro and macro practitioners. The ethical

principle of social justice calls for social workers to
pursue social change through advocacy and political
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activism. Recently, social workers and mental health

clients marched on California's state capital advocating
for increased mental health funding. Their advocacy was

successful as California voters passed Proposition 63,
the Mental Health Services Act, which will generate an
estimated $650 million during the first fiscal year,

2005-2006 (California Department of Mental Health, 2005).
Currently, micro and macro level social workers are
working on planning teams with other mental health
professions creating a three-year plan for Proposition 63

funding expenditures. Once funding is awarded, macro
practice social workers will collaborate on

multidisciplinary teams, designing new mental health

programs, and expanding existing programs to address such
issues as treatment nonadherence with populations like

those with SPMI. Without the advocacy of macro and micro
practice social workers, community-based agencies will

continue to be under staffed and under funded, making it
difficult to initiate effective evidenced-based treatment
that address nonadherence.
Social Work Roles

Mental health social workers play a multi-faceted
role in the client/professional relationship, including
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advocacy for reduced physical and psychological side

effects of psychotropics, remaining client focused by
bridging the gap between parallel treatment modalities,

working on an inter-disciplinary teams applying a
holistic treatment perspective, and educating clients

about their medication regimen (Bentley & Walsh, 2001,
p. 43). Social workers, committed to these roles,
ethically fulfill their duties and responsibilities as

change agents within the community.
Purpose of the Study

The purpose of this qualitative study was to
identify barriers to psychotropic adherence regimens in

clients with SPMI. Medication nonadherence perpetuates

the cycle of psychotic episodes, which leads to

rehospitalization, incarceration, and homeless nights.
This series of events has been coined "the revolving door
phenomenon" (Hewitt & Birchwood, 2002; Kopelowicz &

Lieberman, 2003). Until mental health professionals

listen to the population they serve and better understand

the reasons for psychotropic nonadherence, treatment

interventions will continue to be noneffective.
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This study was conducted at the Mental Health
Association of Orange County (MHAOC), a community-based

nonprofit agency. This study is in keeping with the
intent of the AB2034 Program, authorized in 1999, by the
California State Legislature, to provide intensive

recovery services to individuals diagnosed with a SPMI

such as schizophrenia, schizoaffective disorder, bipolar
disorder, and major depressive disorder, .secondary

diagnoses of substance disorders., and homelessness or
being at risk of becoming homeless. These individuals are

referred to the AB2034 program through Orange County

Department of Behavioral Health, Homeless Outreach
Program.
The AB2034 program serves adults over 18 years of
age, both male and female, representing diverse cultural

and religious backgrounds. With respect to individuals'
cultural beliefs, practices, and personal goals, case

managers link clients to practical services that promote
recovery and social integration. These services include

counseling, pharmacotherapy, housing, financial support
through SSI, medical and dental benefits, food and

clothing, detoxification, rehabilitation programs, and
social skills training.
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Studies identify numerous reasons for psychotropic
nonadherence such as adverse side-effects (i.e. excessive

weight gain, sexual dysfunction), client/clinician
relationship, lack of insight, and complexity of
medication regimen (Azrin & Teichner, 1998; Balon, 2002;

Dixon et al., 1997; Edlund, Wang, Berglund, Katz, Lin &
Kessler, 2002; Hewitt & Birchwood, 2002; Kane & Nemec,

2002; Love, 2002; Nasrallah & Korn, 2002; Rosenberg,
Bleiberg, Koscis & Gross, 2003). Recent studies of

psychotropic nonadherence indicate a significant
correlation with the client/clinician relationship

(Balon, 2002; Donnell, Lustig & Strauser, 2004; Gabbard &
Kay, 2001; Kane & Nemec, 2002; Noordsy et al., 2002;

Trauer & Sacks, 1998). Creating a positive, mutual
working relationship is vital to adherence practices of

those with SPMIZ which essentially promotes recovery.
Offering clients, especially those hard to reach, the

opportunity to enhance their standard of living, guides
this studies methodological rational.

Research Design

This research study is exploratory in nature and

used a qualitative research methodology to elucidate the
reasons for psychotropic nonadherence, from the SPMI
7

individual's perspective. The instrument used in this

study was specifically designed to draw out participants'
responses to psychotropic adherence questions based on

their own experiences and perceptions. Due to limited

research in this area no standardized measure was
available. Data was collected through a semi-structured

interview and recorded verbatim. Using a table of random

numbers, researcher selected a random point on the table,

reading across the rows, or down the columns, writing a

list of the first 20 numbers found. These 20 numbers were
used to identify the sample of this study.
A Licensed Family and Marriage Therapist

administered the Mini Mental Status Exam (MMSE) to

prospective participants to asses their current mental

status. A minimum score of 21 was used to screen
prospective participants into this study. After
participating in the semi-structured qualitative
interview, participants received an envelope containing

$15 cash in return for their time and effort.

Significance of the Project for Social Work

This study is important to social work practice

because it validates the principles of empowerment by
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seeking a deeper understanding of the client's reasons

for psychotropic nonadherence. Using a client-centered

approach, researchers will engage clients with SPMI

through personal interviews. Engagement is a powerful
element of the working alliance supporting the ethical

principles of social work practice. Furthermore, engaging

clients and offering them the opportunity to discuss

psychotropic regimen concerns, enhances the individual's
inherent feelings of worth and self-determination.

Findings from this client-centered study provide a unique

insight into adherence issues that will inform both the

design and implementation of new treatment approaches.
Furthermore, approaching nonadherence issues from

the client's perspective helps mental health

professionals move from the biological confines of the
medical model that often perpetuates victimization to a

more hopeful model of recovery that promotes quality of
life (Ragins, 1994). Strategies which attempt to improve

adherence through increased dosage, change in medication,

or modifying the formulation (oral to depot) are

typically unsuccessful (Ragins, 1994).
Effective community-based.mental health agencies
serving those with a SPMI use a dual-modality therapy
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approach. Dual-modality is a combination of psychosocial

rehabilitation (including psychotherapy) and
pharmacological treatment. Crate (2003) notes that

psychosocial rehabilitation is based on a number of
psychological theories including: client-centered,
rational emotive, and reality theory. Each of these
theories promotes the ideal of client self-determination

through conscious decision-making, an essential component

of recovery.

Pharmacological treatment was ushered in the 1960's,

and played a central role in the early stages of
deinstitutionalization (Heyscue, Levin & Merrick, 1998).
Psychotropic medication is the single leading treatment

modality in mental health care nation wide, offering

quicker relief from psychotic symptoms than psychosocial
rehabilitation. Both treatment modalities have a place in

the field of mental health, however, combining these

treatment modalities (i.e., psychosocial rehabilitation

and pharmacotherapy) produces the best results.
Several studies of psychotropic nonadherence have
called for further investigation of treatment adherence.
With over one-half of persons' with a SPMI nonadherent to

psychotropic regimens, mental health social workers
10

continue to seek answers■to address this crisis. The

evaluation phase of this study is essential to the

identification and implementation of effective
interventions in the field of mental health social work.

11

CHAPTER TWO

LITERATURE REVIEW
Introduction

This chapter will describe severe and persistent
mental illness, determine costs involved in serving
individuals with such illnesses, and the barriers to

psychotropic adherence. It will also describe the
different treatment modalities that are utilized with
this population. For example, psychosocial therapy based

interventions will be discussed in terms of improving

medication adherence and insight into illness, and
interventions based solely on pharmacotherapy.

Dual-modality interventions that include psychosocial
therapy and medication to assist severe and persistent

mentally ill (SPMI) clients are also discussed. Finally,
a discussion of the theories guiding this research

project will conclude this chapter.
Severe and Persistent Mental Illness

Severe and persistent mental illness (SPMI) is
determined by Federal regulations and "applies to mental
disorders that interfere with some area of social
functioning" (USDHHS, 1999) . The areas of social
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functioning include problems with primary support group,
social environment, education, occupation, housing,

economic stability, access to health care services, legal

system/crime, and other psychosocial and environmental
areas (DSM-IV TR, American Psychiatric Association,
2000).

Two components that warrant attention when
addressing SPMI are the human and financial components.

The human components are the problems that individuals
with SPMI encounter, which include profound functional

impairment in one or more of the above mention areas, and
leads to loss of functioning in many different areas of
life. The Advisory Mental Health Council estimated that
nine percent of U.S. adults have mental disorders as well

as deficits in functional abilities (as cited in USDHHS,
1999).

The financial component involves the direct and
indirect costs involved in serving SPMI clients. The

category of direct costs includes "mental health

institutions, sheltered homes, drugs, support costs, and

social welfare" (Lindstrom & Bingefors, 2000, p. 114).
The indirect costs are computed as loss of productivity

in the workplace, school, and home due to premature death
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or disability (USDHHS, 1999) . In 1996, the direct costs
of mental health services totaled 69 billion dollars

(USDHHS, 1999) . Additional indirect costs were calculated
in 1990 to exceed 78 billion dollars (USDHHS, 1999). In
addition to these direct and indirect costs to humanity,
overall reduction in the quality of life for the clients
should also be included (Lindstrom & Bingefors, 2000).

Barriers to Psychotropic Adherence
Many different barriers to medication adherence have

been discussed in the literature. Barriers to medication

adherence include, but are not limited to the following:
medication regime confusion, lack of insight (into mental

illness), denial of diagnosis, cultural belief systems,

self-medication with illicit drugs and alcohol, side
effects, and relationship between client and clinician.

Side effects and relationship between client and

clinician appear to be the two most important factors in

treatment adherence. In fact, Seedat, Stein, and Wilson

(2002) examined the drop out rates of clients engaged in
treatment (pharmacotherapy and psychotherapy), noting

that almost one-half (45.6%) left.treatment due to side
effects.

14

Lack of Insight
Programs operating under the psychosocial model
assist clients with psychotropic regime confusion, lack

of insight, and denial of diagnosis. Lack of education

was associated with medication nonadherence, discovering
that clients were poorly informed of their diagnosis and
treatment. Nearly one-half of those respondents

discontinued medications due to side effects (Seedat et
al., 2002). Louis-Simonet et al.

(2004), on the other

hand, utilized residents to perform a structured

patient-centered discharge interview, concluding that

patients exited the program with significantly increased
knowledge about their medications. This study did not

yield statistically significant results, most likely

based on the lack of social support once clients were
released from the hospital (Louis-Simonet et al., 2004).

Increased knowledge of medications in combination

with social support has been shown to increase medication
adherence (Ho et al., 1999). Hellwell (2002) also noted a
link between insight into illness and medication

adherence; in fact one out of five clients diagnosed with
schizophrenia missed one week of medication during the

first three months after hospitalization. Jordan,
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Tunnicliffe, and Sykes (2002) developed the SPMI clients'

insight into illness and side effects of medication
regimes by utilizing a checklist to assist clients to

determine medication side effects. This checklist allowed
clients to report unfavorable side effects in a timely

manner to the psychiatrists once they understood that
side effects were possible (Jordan et al., 2002).

Stawar and Allred (1999) discovered that the
perceptions of the staff members and the clients differed

considerably when concentrating on discontinuation of
medication. They noted that very few staff members

perceived confusion as a reason for medication
nonadherence, whereas more than one-third of the

residents did perceive it as such (Stawar & Allred,
1999).

Cultural Barriers
Cultural barriers can further complicate

psychotropic adherence in many different populations.
Minorities encounter many barriers to receiving mental

health services. "Mistrust and fear of treatment;
different cultural ideas about illnesses and health;
differences in help-seeking behaviors, language, and
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communication; racism; varying rates of being uninsured;
and discrimination by individuals and institutions" are

many of the cultural barriers faced by minorities in
receiving mental health services (New Freedom Commission

on Mental Health, SMA-03-3832, 2003). Stotland (2003)
noted that unspoken fears, such as the barriers listed

above, affect the treatment regime. These fears can
manifest in cultural beliefs that prevent a client from

receiving greatly needed services.
For example, Asian culture views the mind and body

as "unitary" compared to the European ideal of

"dualistic". This belief tends to manifest in Asian
patients as physical indicators, versus emotional

symptoms (Lin & Cheung, 1999) , as mental illness is
viewed as shameful. This can be a barrier, as Asian

clients might not seek mental health services, due to the
belief that the problem is physical.

The National Institute on Mental Health (USDHHS,
1999) notes that the U.S. mental health system-is not
equipped to meet'the needs of ethnic and racial minority
populations. Cultural barriers (i.e., cultural beliefs)

deter ethnic minorities from seeking treatment, and if
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individuals seek treatment, their treatment plans may be
inappropriate in nature (USDHHS, 1999).

Self-medicating Behaviors
Self-medicating (i.e., utilization of illicit drugs
and/or alcohol) to reduce symptoms of SPMI clients is a

direct barrier to medication adherence. Johnson, Brems, &
Burke (2002) examined 104 clients in a substance abuse

program, identifying 45 percent with an additional mental

illness, indicating that many times the two problems
cannot be separated. Ho et al.

(1999) adds that treating

dually diagnosed individuals is increasingly difficult as
clients face "increased morbidity from substance induced

psychotic exacerbation, dysphoria, anxiety, insomnia, and
agitation" (p. 1765).
Side Effects
Studies with SPMI clients have demonstrated side

effects in drug treatment plans as a major cause of
medication discontinuation. Side effects range from

weight gain to sexual dysfunction. Green, Patel, Goisman,
Allison, and Blackburn (2000) state that psychotropic

drugs used to treat schizophrenia have been linked to
substantial weight gain. Green et al.,
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(2000) examined

obesity in schizophrenic clients, noting that these same

clients are at risk for. additional physical ailments such
as Type II diabetes. Sexual side effects (i.e., sexual

dysfunction, lack of desire, etc.) were reported by 62.5

percent of males and 38.5 percent of females in a study
conducted by Rosenberg et al.

(2003). Of particular

interest is that 50 percent of the clients "never or

infrequently" voiced these concerns to their clinicians
(Rosenberg et al., 2003). These findings suggest that the

relationship between the client and clinician needs to be
open, honest, and safe, allowing clients to voice their
symptoms/side effects with psychotropics.

Cognitive difficulties have been noted in previous

studies as a result of psychotropic medication use. In
fact, Hellwell (2002) noted that many clients experience

problems with cognitive abilities such as rigidity or

dullness of thinking. These cognitive difficulties can
contribute to psychotropic medication nonadherence, as

well as confusion of regimes.

Physical aliments are identified in studies

describing side effects of psychotropic medication use.
Fincke, Miller, and Spiro (1998) note that clients
reported an increase in physical illness while on
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psychotropic medications, including, "nausea,

indigestion, headache, blurred vision, dizziness, dry
mouth, and itchy skin" (p. 184). Additional physical
ailments discussed in the literature include psoriasis,

acne, and hair loss. These side effects have been found
among 45 percent of clients on a Lithium regime (Yeung &

Chan, 2004). Hair loss has also been identified in

studies of antidepressant use in adolescent quality of
life (Cheung, Levitt, & Szalai, 2003) .

Relationship between Client and Clinician
Another barrier to medication adherence is the

relationship between clients and their clinicians.

Lindstrom and Bingefors (2000) noted that the attitudes

of clinicians towards clients affects clients' adherence.

Other factors that reduced medication adherence were the
clinicians' "authoritarian attitude, aloofness, passive

behavior, indifference, anger, denial, cynicism,
hopelessness, and ignorance" (Lindstrom & Bingefors,

2000, p. 113). Kerse et al.

(2004) studied medication

adherence in comparison with physician/patient

relationship and discovered that "trust and
physician/patient concordance were significantly related
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to compliance" (p. 455). These findings suggest that
improving the relationship between clients and their

clinicians can have long-term effects on medication
compliance (Kerse et al., 2004).

Treatment

The treatment of SPMI includes psychosocial therapy,

pharmacotherapy, and dual-modality services (i.e., a
combination of the two) for. clients. Evidence-based

practice finds that a dual-modality approach to SPMI

clients increases psychotropic adherence (Bentley,
Rosenson, & Zito, 1990). Pharmacotherapy includes oral

and intramuscular psychotropic medications. Psychotherapy

utilizes individual and group therapy typically
psychoeducational in nature to promote insight. Smith,'
Birchwood, and Haddrell (1992) noted that many SPMI

clients lack knowledge about psychotropics, which can
lead to lowered adherence rates.
Psychosocial Rehabilitation

Psychosocial rehabilitation (i.e., psychoeducation)
targeted to SPMI clients regarding drug regimes, illness,
and side effects can help increase insight. Yet, mixed
findings exist. Increased insight can improve clients'
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medication adherence. However, studies that base
interventions in psychosocial rehabilitation, without
utilizing additional facets to assist clients, fall short

of the goal of increased psychotropic adherence (Hayward
& Chan, 1995; Kavanagh, Duncan-McConnell, Greenwood,
Trivedi, & Wykes, 2003; Smith et al., 1992).

Assertive Community Treatment (ACT) is an "intense

mental health program model in which a multidisciplinary
team of professionals serves patients who do not readily
use clinic-based services, but who are often at high risk
for psychiatric hospitalization" (Bond et al., 2001). ACT

has been found to increase medication adherence among the
homeless population. Dixon et al.

(1997) studied a group

of homeless individuals who voluntary received services

from a clinical team that employed the ACT program. The
results of this treatment modality included rapid
increase in medication adherence among the homeless

population, as well as fewer psychiatric symptoms (Dixon
et al., 1997).

Pharmacotherapy
Many interventions targeted for SPMI clients include

pharmacotherapy. Psychotropic adherence is a main concern
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for many clinicians working with SPMI clients, as
re-hospitalizations are costly to the public. Many

studies analyze tactics for increasing psychotropic
adherence. Love (2002) investigated the strategies

employed to increase medication adherence and noted that

depot psychotropic medications (i.e., intramuscular
injection of a psychotropic medication) utilized with
non-adherent clients were more effective when combined
with social support. He also found that atypical

psychotropics (i.e., second-generation anti-psychotics)
with improved efficacy and tolerability, increased

adherence and reduced hospitalizations compared to the

depot and oral medications (Love, 2002). Love's (2002)
findings should be heeded as a significant number of

hospitals and community mental health centers are being
sued for incompetence, neglect, and even abuse in

relation to clients'' adherence to psychotropic medication
(Gerhart & Brooks, 1983).

Dual-modality Interventions
Programs that utilize a combination of psychosocial

rehabilitation and pharmacotherapy have significant
results in regards to increased psychotropic adherence.
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Ho et al.

(1999) utilized psychoeducational groups to

increase clients' insights into their illness and
psychotropics, employing the ACT program that "enhanced

the engagement process by maximizing patients' access to
social and rehabilitative resources" (p. 17 68).. The
results of Ho et al.

(1999) included increased engagement

rates, fewer hospitalizations after entering the ACT

program, and abstinence from illicit drugs (measured by
urine toxicology).
Utilization of dual-modality treatment markedly

increased rates of psychotropic adherence for clients
with chronic mental illness. Azrin and Teichner (1998)

utilized family support and psychoeducation to increase
adherence rates. They utilized a control group and an
experimental group, where the control group received
information based solely on the medication, and the

experimental group received an in-depth educational

program that included the client and the family receiving
information about the drug regime. The program increased

adherence to 94 percent in the. experimental group,

whereas the control group's rate of adherence was 73
percent (Azrin & Teichner, 1998).
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Skinner (2005) worked with the mentally ill homeless

population by employing psychoeducation and a program
that he termed Modified Therapeutic Community (MTC). MTC

is similar to ACT, where clients' individual treatment
plans revolve around psychosocial rehabilitation,

support, and pharmacotherapy. Skinner (2005) utilized a

quasi-experimental design and compared the MTC group to a
group of homeless individuals at a general shelter. The
general shelter did not incorporate all the needs of the

client, only housing. The MTC experimental group had a

significantly lower percentage of individuals
hospitalized and/or transferred to a high level of care

facility when compared to the population in the general
shelter. Skinner's (2005) MTC group also had higher rates

of medication adherence compared to the control group
(81.4% versus 64.7%, respectively).

Theories Guiding Conceptualization

There are several theories discussed in the
literature regarding medication adherence. Social

learning theory is based on behavioral theories that
focus on observable behaviors, rather than internal
motivations, needs, and perceptions of individuals

25

(Zastrow & Kirst-Ashman, 2004). Social learning theory

focuses on behaviors and how these are learned. It

assumes that behaviors can be changed with positive .
reinforcement (Zastrow & Kirst-Ashman, 2004). Social
learning theory includes a "positive orientation to

treatment that attempts to build patients'
self-awareness, awareness of others, and coping skills"

(Bedell, Hunter & Corrigan, 1997). Studies that utilize
any form of psychosocial education to increase clients'

insight are employing social learning theory (Hayward &
Chan, 1995; Kavanagh et al., 2003; Smith et al., 1992).

Another theory that has guided research in this area
of study is compliance theory. Compliance theory is a

health-belief model asserting that:
individuals will take action, seek care and
comply with health regimes if they regard
themselves as being susceptible to the

condition in question, if the condition has
serious consequences, if the action would be

beneficial and if they feel that the barriers
to action are outweighed by the benefits

(Lindstrom & Bingefors, 2000) .
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This model utilizes sociodemographic factors,

particularly education, when describing behaviors

(Lindstrom & Bingefors (2000) . Behaviors are influenced
by the perceived severity of illness and benefits of
medication, as well as barriers. Rietveld and Koomen

(2002) describe the health belief model in terms of seven
determinants of compliance behaviors: "when pain would

remit, the cause of pain, the mysterious nature of pain,

how pain alters life style, personal control of pain,
regarding blame for pain, and whether pain is experienced
constantly of intermittently" (p. 625). Psychosocial

rehabilitation addresses self-determination through
social skills group training, which can lead to increased
adherence, the ultimate goal of many research projects.

The theory guiding this research project is
client-centered theory. Carl Rogers developed this theory
from his self-theory describing a person as the result of

his/her experiences and how he/she perceives those
experiences (Zastrow & Kirst-Ashman, 2004). This theory

focuses on the "way of being" with the client, as opposed
to the "way of doing" things for.the client (Corey,

2000). Corey describes the sense of trust that enables
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the client to move forward and grow (2000) . Faith in the
person is one of the basic premises of this theory, the

faith that each person can be trusted (Corey, 2000) . This
research project aims to understand client nonadherence
to medication while increasing trust between clinicians

and clients. The conceptual framework of the
client-centered theory is that clients will become more
honest with clinicians once they feel that they are

understood and respected by those same clinicians

(Thorne, as cited in Corey, 2000).
Summary
This chapter discussed severe and persistent mental
illness, as well as outlines the costs (direct and
indirect) involved in serving individuals with SPMI.

Barriers to medication adherence are discussed in detail

as well as the different treatment modalities utilized
with this population. Psychosocial therapy based

interventions are discussed in terms of improving
medication adherence and insight into illness.

Interventions based solely on pharmacotherapy and

dual-modality interventions, those that combine

psychosocial therapy and medication to assist SPMI
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clients is discussed. Finally, the theories guiding this
research project concludes this chapter.
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CHAPTER THREE
METHODS
Introduction
This exploratory study was conducted using both a

qualitative and quantitative measurement method to
explore, from the clients'' perspective, barriers to

psychotropic medication adherence. This chapter will
discuss the study design, sample from which data was

collected, method and instrument used for data

collection, data analysis, and procedures taken to
protect confidentiality and anonymity for human subjects
in this study.
Study Design

The purpose of this study was to explore the
barriers that cause psychotropic nonadherence in

individuals with severe and persistent mental illness

(SPMI). Clients were encouraged to share information in
relation to their experiences with psychotropic
medication regimes during a semi-structured, one-on-one

interview. The interviewer administered the study

questionnaire that included both a quantitative and a
qualitative component. The demographic component
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contained information such as; age, gender, number of
hospitalizations, diagnosis, etc., while the qualitative
portion explored barriers to psychotropic adherence from

the client's perspective, through open-ended questions.
Methodology implications for this study are based on

the guiding principles of the psychosocial rehabilitation
and recovery model. These principles promote

self-determination by supporting persons with SPMI,
encouraging them to make their own choices, and involving

clients in their own treatment planning. By providing

individuals with the opportunity to express their own
needs and desires, mental health workers minimize

professional distance and create empowering adult-to

adult relationships (Ragins, 1994).
Clients may have benefited from participation in
this study by learning the importance of self-advocacy,

enhancing self-esteem, and understanding the importance

of mutual working relationships with mental health

professionals. This project was an exploratory study of
barriers to psychotropic adherence from the client's
perspective. By inviting individuals to voice their

mental health concerns, this study supported•the consumer
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movement motto: "Nothing about us without us" (National

Mental Health Association, 2005).

Limitations

There are several limitations of this study. Social
desirability, answering questions in the direction of the

interviewers perceived needs or wants, is unavoidable in
this study due to the design. Nancarrow and Brace (2000)
examined the causes of social desirability bias (SDR),

ways of detecting bias, and techniques used to reduce the
problem. They concluded that there is no way to reduce or

eliminate social desirability because establishing that

it actually took place is difficult.
A second limitation is use of a non-standardized

instrument. A standardized instrument addressing
medication nonadherence from the participant's

perspective could not be located. Researchers designed a
questionnaire (Appendix A), specific to this research,

for the interview process. To ensure content validity,

researchers conducted a two-phase pretest.

Phase one, employed mental health professionals
(i.e., case managers), serving individuals with SPMI, to
review the interview.questionnaire and provide.critical

feedback. This segment of the pretest identified poorly
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worded interview questions, questions revealing the
researcher's bias, and culturally sensitive wording.

Phase-two tested the interviewer's ability to deliver the
study instrument effectively. Case managers were given a
questionnaire to score the wording of questions, the

interviewer's ability to communicate clearly, and the
interviewer's approach to the interview process (Berg,

2004, p. 90). Additionally, the pretest provided

researchers with the opportunity to test the interview
environment and determine the duration of the interview
and debriefing process.

The final limitation in this study is a result of
purposeful sampling. Because this study addresses a

specific problem, within a distinct population, purposive
sampling requires that participants have certain
characteristics in common in order to be selected for an
interview. The selection criteria for this study included

persons' with a SPMI, receiving mental health treatment
from the AB2034 program, male and female, and a minimum

of 18 years of age. Furthermore, external validity is

limited because the participants are from one agency;
making it difficult to generalize study findings.

Notwithstanding these limitations, this exploratory study
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provided valuable insight to psychotropic nonadherence

from the most reliable source, individuals diagnosed with
a SPMI.

Sampling
A simple random sampling of participants consisting

of, males and females at least 18 years of age, diagnosed
with a SPMI or co-occurring disorder (COD), i.e., mental
disorder and substance use was employed(DHHS Publication

No.

[SMA] 05-3992, 2005). These individuals are currently

receiving intensive recovery services through the AB2034

program at the Mental Health Association of Orange

County, California. Of the 99 clients currently enrolled

in the AB2034 program, this study included 16 individuals

as participants.
To select a sample of 16 individuals, each client

was first assigned a number between 1 and 99. Using a
table of random numbers (Appendix B), researcher will

picked any point on the table, reading across the rows,
or down the columns, writing a list of the first 16
numbers found. These 16 numbers identified the 16

participants that made-up the- sample for this study. Each
person selected for the study was provided with a
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recruitment flyer, hand delivered by his or her case
J
manager, which provided information such as the time,
date, and possible benefits for participating in the
study (Appendix C). Next, identified participants were

then phoned by the researchers and asked if interested in

participating in this study.

Permission to conduct this study was granted after

review of the project proposal by Keith Parker LMFT,
AB2034 Program Director for the Mental Health Association

of Orange County, California.
Data Collection and Instruments

The survey instrument was a 10-item, one-to-one,

semi-structured interview. Open-ended questions were

designed to generate possible reasons for psychotropic
nonadherence. Examples of interview questions included,
"Can you tell me why you take medications?"; "Do you

believe it is your decision alone to take medications?

Who do you believe makes this decision?" and "How have
medications helped you". Examples of demographic

questions included, "What is your currently living
situation?"; "What is your diagnosis?" and "Including all

mental health agencies, how long have you been receiving
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mental services?" Both components of this study,
demographics and qualitative interview, use a nominal
level of measurement.

Due to the lack of qualitative studies on

psychotropic adherence, this questionnaire was uniquely
designed to explore possible barriers to adherence, from

the participant's perceptive. To ensure content validity,
this study instrument was designed based upon previous

studies cited in the literature review.

Procedures
Data collection took place on Fridays between the

hours of 8:00 a.m. and 3:00 p.m., over a period of

two-weeks. Interviews were held at one of the Mental
Health Associations of Orange County's clinics. To ensure

confidentiality, interviews were conducted in a private
office. Interview sessions range from 15 - 40 minutes.
A Mini Mental Status Exam (MMSE)

(Appendix D) was

administered to individuals interested in participating
in this study. The AB2034 Program Director, a Licensed

Marriage and Family Therapist (LMFT), agreed to perform
the MMSE on each person wishing to participate. This
measure was taken to ensure the individuals' cognitive
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appropriateness to participate in the study at this

particular time.
The LMFT administering the MMSE followed Folstein &
Folstein's, suggested guidelines for scoring as noted at

the bottom for the MMSE form. Participants scoring more
than 21 points out of the maximum 30 point were invited

to participate in the study. Participants scoring less
than 21 points were not eligible to participate in the

study due to mild-moderate cognitive impairments.
Fortunately, no participants were turned away due to

scores under 21 points. Participants received an envelope

containing $15 cash in return for their time and effort.

Upon receipt of the $15 cash gift for participating,

participants were asked to sign a receipt form by placing
an "X' in the box. This method of signature for receipt

of funds was instituted to maintain the participant's

privacy and to keep their information confidential.
All data and client information, MMSE, interview
questionnaires, and interviewers' notes was contained in

a locked file cabinet within the locked office of the
program director.
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Protection of Human Subjects

Several measures were taken to protect the
confidentiality of the participants in this study. All
participants in this study were voluntary. The
questionnaires used during the interview utilized an

identification number rather than the participant's
names. Informed consent (Appendix E) was obtained by
using forms and procedures approved by the institutional

review board. Documentation of informed consent was read
aloud and explained to each participant. Participants

agreeing to the study were asked to place an "X' in the

box on the consent form labeled "YES". This method of

identification and signature of consent was instituted to
maintain the participant's privacy and to keep their
information confidential. To maintain confidentiality,
any documents containing participant information were

only accessible to the researchers and their research

advisor.

Participants were informed at the beginning of the
interview that they did not have to answer any questions

they believe to be too personal. Furthermore they were
informed that they had the right to refuse answering
any/or all questions without explanation or penalty. The
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interviewer informed participants that the study was

voluntary and that they could discontinue the interview
and leave at anytime. Participants were informed of the

confidential nature of their responses. At the end of the

interview, researchers provided participants with a
debriefing statement (Appendix F), which was read aloud

and explained. Participants were informed of how they

obtain study results and were provided with names and
numbers of mental health agencies on the debriefing

statement, in case participants became distressed.
Data Analysis

Qualitative data analysis was used for participant's

responses to open-ended questions during a one-to-one
semi-structured interview. Researchers identified
cultural domains for participants' responses to all

open-ended questions based on underlying association of
content. The responses derived from this study could be

used to create new treatment interventions and recovery
planning.

Summary

This exploratory study used both a qualitative and
quantitative measurement method to explore, from the
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client's perspective, barriers to psychotropic adherence.

This chapter discussed the study design, sample from

which data will be collected, method and instrument used
for data collection, data analysis, and procedures taken

to protect confidentiality and anonymity for human
subjects in this study.
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CHAPTER FOUR
RESULTS

Introduction
This chapter describes the demographics for the

study group using a quantitative method of data
collection and the major themes that emerged using a

qualitative method, open-ended questions, concerning

reasons for psychotropic medication nonadherence.

Verbatim responses from participants as recorded in
one-on-one interviews are provided allowing consumers of

mental health services a chance to be heard.

Presentation of Findings
Demographics for eligible participants consisted of
16 adults receiving mental health services from the
Mental Health Association of Orange County, AB2034
Program. In terms of gender, 62.5% of the participants

were female and 37.5% of the participants were male

(Table 1). The mean age was 42.3 years old (Table 2).
The sample was composed of 50%. Caucasian., 18.8%

Black or African American, 18.8% other of which one
participant sincerely replied, "I am capital, NEGRO,
Negro," and 12.5% of participants refused to answer the
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question (Table 3). Of the 16 participants involved in

the study, 50% were single/never married, 6.3% were
separated, 37.5% reported being divorced, and 6.3% were

widowed (Table 4). A majority of the participants 93.8%
reported being unemployed (Table 5), while 31.3% reported

having.a high school diploma or the equivalent, and 37.5%
reported having some college or a two-year college degree
(Table 6).
Within the past 12 months of administering the

questionnaire, 12.5% of the participants stated that they

had been hospitalized for psychiatric care, and 12.5%
were incarcerated. Another 12.5% were both incarcerated

and admitted to a psychiatric hospital, 6.3% were both

incarcerated and received detoxification treatment for
substance abuse, 6.3% received detoxification treatment
for substance abuse only, and 50% reported no

hospitalization, incarcerations, or substance use
treatment (Table 7).
Participants were asked, "Including all mental

health agencies, how long have you been receiving mental

health services?" Findings declared that 6.3% had been
receiving services for less, than 2 years, 25% stated 2 -

5 years, 12.5% fell between 5-7 years, 12.5% claimed 7
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- 10 years, and 43.8% said they had received services for
more than 10 years (Table 8).
Finding permanent housing for persons with a severe

and persistent mental illness can be challenging.
However, this study revealed that 56.3% of the

participants live independently, meaning, they rent an

apartment in the community. Furthermore, 12.5% reside in
sober living facilities, 6.3% live with family members,

6.3% stated other living arrangements (possibly a hotel
room), and unfortunately 18.8% remain homeless (Table 9).

All participants in this study are diagnosed with a

severe and persistent mental illness (SPMI) and
diagnostic types were not reported. Self-reported

diagnosis included 31.3% Schizophrenia, 31.3% Bipolar

Disorder, 12.5% Schizoaffective Disorder, 6.3% Major
Depressive Disorder, and 18.6% reported multiple

diagnosis with conflicting diagnostic criteria (Table
10) .

Using the most recent clinical documentation
reported by the clients' attending psychiatrist and
participants' self-reports, 31.3% of the

client/psychiatrist diagnoses matched, 31.3% did not
match, and 37.4% matched part of the reported diagnosis,
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but not the complete diagnosis. These findings lead to a
comparative analysis of clients' self-reported medication

regimen versus the psychiatrists' documentation of
prescribed psychotropic regimens.
The comparison of clients' self-reported

psychotropic regimens versus psychiatric records revealed
that 31.3% of the clients had accurately stated their
prescribed medication, of which 31.3% reported completely

different psychotropic medications than documented by
their psychiatrist; 31.3% reported some of the same

medications as were documented, but not all; and 6.1%
reported taking psychotropic medications while their

records indicated that they were no longer receiving
pharmacotherapy treatment.
Participants were asked the same questions, in the

same order. Each set of questions were designed to

illicit reasons for adherence/nonadherence to

psychotropic medication regimes from the participants'
perspective. Several content categories emerged from the
participants' verbatim responses, some of which will be

provided to illustrate the nature of their concerns.

The first set of questions explored current use of
psychotropic medications and their perceived benefits, if
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any. "Are you currently taking medications for a mental
illness?" Which was followed by one prompt, "Pills or

shot?" All participants said they were currently taking
medications, of which 93.7% stated they were taking their

medication in pill form and 6.3% said by shot. Given the

severity of the participant's mental illnesses, and the
high rate of psychotropic nonadherence within this
population, researchers suspect some level of social

desirability effect.

The next was, "Can you tell me why you take
medication?" Nearly 70% (68.8%) of the participants

stated that they took psychotropic medications to address
symptoms caused by a mental illness, while 31.2% simply

stated that they took the prescribed medication because
they were diagnosed with a mental illness. One of the
participants responded to this question by saying,

"Because I have racing thoughts, unable to sleep, massive
mood, swings, violent, quite the shopper when not on

medications." Another participant responded by saying,
"Because I have been diagnosed with schizophrenia in
1990."

This question was followed by one prompt: "How have

medications helped you?" Once again the majority, 68.4%,
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stated that medications helped to reduce, symptoms, 21%
reported increase ability to function in daily
activities, 1% found the medications non-effective, and

1% did not have an understandable response. A participant
that believed medications helped reduce symptoms said,

"Helps me to sleep, helps me when I hear voices, when I
do not take them I get depressed, it stabilizes my mood."
A participant that reported an increase in functioning
stated, "Helps a great deal, helps me function, even

though I do not have a job or anything constructive, I

can get the basic needs: food, not afraid to deal with .
social environment." The participant that found
psychotropic medications ineffective responded by saying,

"I do not really feel a difference, but I do not feel
mentally ill either."
When asked, "Tell me reasons why you do not like

taking your medication?" 72.7% of the participants stated
they did not like taking psychotropic medications due'

negative side effects, 9.1% identified feelings of

depersonalization, 9.1% found psychotropics inconvenient,
and 9.1% said the medications were ineffective. One of

the clients concerned with negative side effects stated
that the medication, "Make me feel sick and very sleepy
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or worse than I am feeling." The participant expressing
feelings of depersonalization replied, "Makes me feel
different at times, different than other people, I feel

ok and if I continue the medications it might induce

something to make it worse." Another participant stated
that taking medications were inconvenient, "Cuz it's a

hassle to take them, remembering to take them."

Ineffectiveness was expressed as,

"One reason, it doesn't

help much. I am kind of scared of them too, they may hurt
my body."
The following prompt was asked after the previous
question to evaluate participants' willingness and/or

opportunity to seek help to manage medication regimens:
"Have you talked to anyone about this?" Most of the

participants (66.7%) said that they had talked to
someone, 25% stated they had not talked to anyone, and
8.3% stated that they attempted to talk with someone. One

of the participants said, "Yes, 1 talk to other clients
and doctor." Another client attempted addressing

medication concerns stated, "Try to talk to doctor about

it, yet we do not have anytime. But I would like to."
The next set of questions deal with the
participants' environment, relationships, illicit drug
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use, and mental health services they may have received or

would like to receive.
The first question was, "Can you remember a time
when you decided not to take your medications?" The

response was almost split evenly: 56% replied, "yes",
while 43.7% relied "no." The follow-up probing question

was then asked of all participants: "Can you tell me what

was going on in your life at this time?" Active
psychiatric symptoms were reported by 75% of the
participants. One participant stated, "I was religiously

preoccupied, had the desire to be functionable without
medication. Spiritually I felt I had to be off
medications, I don't feel that way now, voices were being

crafty, evil voices telling me to take the medications,
anyone would be scared." Furthermore, 12.5% reported
physical aliments, and 12.5% reported being in denial of

having a mental illness.

The following question asked participants to discuss
their opinion of their psychiatrist: "How do you feel

about your psychiatrist?" The vast majority, 72.2%, had a
positive response such as, "I like him, able to

communicate. He has respect for me." While 27.8% had a
negative response such as, "He does not say too much. He
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prescribes meds, get therapy elsewhere. Pretty much

in-and-out."

Seeking concreteness, the following probing question
was asked of all participants: "How do you expect your
psychiatrist to treat you?" An appraisal of the
participants' responses resulted in 40% stating that they

wanted to be treated professionally, as interpreted by

one participant's reply, "With a firm hand, he is very

good." Another 25% said that they expected to be treated
respectfully by their psychiatrist: "With respect, just
as I respect him." Furthermore, 25% wanted their

psychiatrist to engage in active listening: "Be a bit
more flexible about lowering the dosage or not taking

certain medications. He wants me to take more to get rid
of the voices. I do not want to take Zyprexa because of
the side effects." Finally, 10% of the respondents said
that they wanted to be treated compassionately, simply

stated as, "Kindly."

The following questions were asked to explore the
possibility of participants engaging in self-medication
practices using illegal drugs. When asked, "Was there
ever a time in your life when you used substances such

as; alcohol, cocaine, marijuana, methamphetamines,
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heroin, etc., instead of your medications?" About (43.7%)
said, "Yes" and 56.3% said, "No." Once again, researchers

believe there to be some element of social desirability
in the participants' responses because most of the
clients enrolled in the program surveyed have

co-occurring disorders.
Of the participants who stated they had used illegal

drugs, a probing question was asked: "Can you tell me why
you decided to do illegal drugs instead of taking your

medication?" 38.6% said they took psychotropic drugs to
reduce psychiatric symptoms: one participant said they
used illegal drugs due to, "Depression." Furthermore,

23.1% replied similarly stating they wanted to feel

different: "T wanted to a different feeling over my body
and mental status." Another 23.1% stated other reasons

for using such as concurrent use: "I used cocaine and

meth and marijuana but not instead of [my prescribed

medication]." In addition, 7.6% faulted their current
living situation for taking illegal drugs instead of
their prescribed medications: "Partly environment,

homeless...." Lastly, 7.6% stated boredom as a reason for
using illegal substances,

"... bored, being poor you have.
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nothing to do, so you take drugs offered to you for
free. "
The next question attempted to identify the mental

health services that participants believed to improve
their quality of life: "Thinking about the mental health
services you have received, what services do you believe
have most improved your quality of life?" The

participants' responses were diverse for example, 22.7%

said that their relationship with their mental health
worker improved their quality of life: "... I have a really

good counselor." Another 18.2% stated that psychotropic

medications played an important part of their recovery.
One participant provided a powerful illustration of their

perceived benefits of psychotropic medications:
"Medications, without it I would be starving myself out

on the street, cold, voices tell me to leave even if I
had a home, don't wear warm clothes, don't eat, don't
move, keep walking forever." Several other services were
mentioned: group therapy (18.2%), individual therapy

(13.6%), educational services (9.1%), food (9.1%), and
housing (9.1%). The following statements further

exemplify services the participants found useful: "The
food, housing, computer room for school and stuff,
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therapy women's group." "Having my own place at an
affordable rate, Section 8 housing way below monthly rate

of rent. Inspections to help get our place more

organized." And,

"Therapy, talking and the medications,

having a place to come to, to focus' on staying healthy

mentally."
The final question, followed by two probing
questions, revealed from the participants' perspective

who they believed controls their decision to take

psychotropic medications or not. Beginning with: "Do you
believe it is your decision alone to take medications?"

Of the 16 participants, 62.5% answered, "No," while 37.5%
answered, "Yes."
Of those participants who believed it was not their

decision alone whether or not to take medications, the

following probing questions were asked: "who do you
believe makes this decision?" followed by, "Can you tell

me more about that?" Sixty-percent of the respondents

believed it to be the doctors' decision alone whether or

not they needed to take psychotropic medications, while
20% stated it was their choice together with their

doctor, and 20% said it was a combination of themselves,
their doctor, and society.
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Whether or not participants believed it was their

decision to take medications, the doctors, or society,

they were given the opportunity to explain their
responses when asked, "Can you tell me more about that?"

Participants' verbatim responses were as follows:
•

"I feel he knows the best about the medications
and what it can do for my mental illness."

•

"It needs to be a joint decision, they have the
knowledge, I have the job of giving approval so

I can get better."
•

"I don't know how to elaborate."

•

"My mind is not ready to make decisions on my
own about medications."

•

"Too little time in the office, I would like a

half-hour to lye on couch."
•

"I take it. I stay on my path of education and

a good job. If I don't take it, I relapse. I do
not want to go through that again. I am
thankful for the chance."

•

"Because in order to receive SSI you must be

following a plan, not taking meds can take you
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off SSI. The doctor can put you in the hospital
to get you regulated when you do not comply."

•

"Because I tell him the medicine is too strong,
he tells me to take it anyway. I will reduce

the dose, pill down to 4 to 6 parts."
•

"I need medication. I went for a physical they
told me to see a psychologist. Then they sent

me to a psychiatrist for medication. That is
why I think that."

•

"Society can interfere by telling doctors,

people, the law, we are being out of control
and give me a diagnosis."

•

"He knows what I need for my mental problems,

what type of medication."
•

"I have struggled with mental illness 4 years
and voices off and on medications. Off meds I

talk to myself, yelling, relationship with

society strained, people think I'm crazy. I
regret what I have said during times I am off

medication and behavior. Experiencing time
without meds make me understand that I need it
and helps me set the right dosages. I used to
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sleep all day, eat all day, get fat, state of

incapitation. It was torture, so I went off."
Summary
This chapter reviewed the results of this research

project derived from participant's verbatim responses
conducted through one-to-one interviews. Data was

obtained from individuals diagnosed with a severe and
persistent mental illness and substance use disorder in

an attempt explain barriers to psychotropic adherence

from the client's perspective. Three themes were found
that might cause barriers to psychotropic adherence;

negative side effects, relationship with mental health
professionals, and insight.
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CHAPTER FIVE
DISCUSSION

Introduction

This chapter will discuss the results of this, study
and how they are essential to the understanding of
clients and their adherence or nonadherence to a
medication regime. It will also discuss the limitations

of the study. This chapter will also provide
recommendations for social work practice. This chapter
will close with a final conclusion of the section.

Discussion

Due to the nature of this exploratory study and the
use of a non-standardized instrument, the researchers
utilized frequencies to■identify significant results. The

percentages were calculated for each question. The

calculations were utilized to identify any relevant

themes noted in the participant responses.
All participants revealed that they were in fact

taking psychotropics for a- mental illness. Over 90
percent of the participants were taking pills, leaving

less than 10 percent currently taking a shot to deal with

a mental illness. Even this first question leaves the
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researchers in a quandary. Social desirability was

believed to affect at least one participant in how they
answered because they recently had their psychotropics

revoked to determine if the identified symptoms were in
fact from a mental illness or due to illicit drug use.

The reasoning behind most of the participants having
pills prescribed is cost. It has been noted to the

researchers that for a client to have monthly injections,

the cost would soar to over $2000.00. The pills are

cheaper and do not require a doctor visit to administer
the medications.
In this study, several themes were found to affect

adherence to a psychotropic regime. Insight., side
effects, and relationship between client and clinician

are a few of the themes identified during the one-on-one

interviews with clients suffering from SPMI.
Insight

In response to the question of "Why do you take

medication?" 68.8 percent of- the participants described
reduction of symptoms from the mental illness (i.e.,
voices lessened, less racing thoughts, etc.). The

researchers accepted these types of responses as an
indication of client insight into their mental illness
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and symptomotology. The remaining 31.2 percent of

participants taking psychotropics do so due to a

diagnosis of a mental illness. The participants appeared
to understand why they take psychotropics, yet they did

not altogether understand their diagnosis or psychotropic
regime.

Less than one-third (31.3%) of the clients surveyed
were aware of their diagnosis. This means that 68.7
percent of the clients surveyed were unaware of their
current diagnosis. This statistic suggests lack of client
insight which can affect their adherence/nonadherence to
a medication regime. If the clients do not know their
diagnosis, how can they possibly understand what they

need to do to help themselves recover? Seedat et al.

(2002) noted that lack of education is associated with
medication nonadherence. In fact, these authors stated
that clients are poorly informed of their diagnosis and

treatment.
Another question that identifies lack of insight is

the medication regime identified by the participant. The
researchers, after conducting the interviews, reviewed

the clients' files to ascertain whether they had answered
these two questions correctly. Again, less than one-third
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(31.3%) of the clients reported the correct medication

regime that they were currently prescribed. This leaves

68.7 percent of participants unaware of their current
medication regime. The participants do not understand
what they had been prescribed or their current diagnosis.

This can be seen as the lack of insight into mental

illness and/or denial of diagnosis. Yet it can be also
seem as a problem with the doctors and how they discuss

the mental health diagnoses and how medication can help.
Clients need to be informed about their illness and

medication regime to increase psychotropic adherence.
As the interviews continued, it was noted that

clients claimed to continue taking medications despite
effective elimination of symptoms. Many clients reported

decreased symptoms, but increased side effects (i.e.,
sleepy, not hungry, too hungry, etc.). Most (72.7%) of
the participants reported talking to friends and family

about their side effects, 25 percent reported not talking
to anyone, and only 8.3,percent of participants who

attempted to talk to their doctor. If participants are
getting information about side effects, mental illness,
and medication from friends and family, they are
overlooking the one individual that has the knowledge and
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ability to help them: the clinician. If clients are
seeking information from the clinician, insight into
their mental illness, symptoms, side effects, and

alternative treatments can be discussed in detail.
Side Effects

When the participants were asked why they did not

like taking their medications, almost three quarters
(72.7%) noted side effects. Another 9.1 percent noted

feelings of depersonalization as the reason for not

taking the medications. Other responses included
inconvenience and ineffectiveness.

The next question was posed to have the participants

speculate on why they might not want to take medications.
When the same participants were asked why they might not

want to take the medications, many answered side effects

(50%). Another 20 percent noted increased symptoms as the

sole reason. The last 10 percent of participants
demonstrated increased, insight into psychotropic regimes

when noting a fear of addiction. Due to the design of
this study, the exact side effects were not identified.
Many clients may have felt embarrassment and chose not to
describe the sexual side effects as a reason for
nonadherence. Many clients noted the sleep side effects
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(whether too much or too little) and the weight gain.

Green et al.

(2000) stated that psychotropics used to

treat schizophrenia have been linked to weight gain.
Clients appear well aware of these side effects. In the
future, the researchers would design the next
questionnaire to more fully identify the exact side

effects experienced by each participant.

Relationship between Client and Clinician
A close working relationship between client and
clinician is helpful in addressing adherence/nonadherence

to treatment plans utilizing psychotropics. The

participants were asked if they had talked to anyone
regarding the reasons why they do not like taking

medications. This question not only suggested clients'
insight into their mental illness, but also the quality

of their relationship with their clinician. As stated
before, over one-half (66.7%) of the participants stated

that they talk to their family and friends, another 25

percent revealed they do not talk to anyone, and only 8.3
percent of the participant's reported attempting to talk

to their doctor. Participants felt that their clinician

did not listen to their concerns, telling them to
continue on the same path. The responses to this question
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are telling in that participants would prefer to talk to
friends and family versus talking to the doctor.
Rosenberg et al.

(2003) found that 50 percent of clients

"never or infrequently" voiced concerns of side effects

to their doctors. This suggests the importance of an
open, honest, and egalitarian relationship between client

and clinician.

The participants were also asked how they felt about
their psychiatrist. Almost three quarters (72.2%) had

positive feelings regarding their psychiatrist. The rest

of the participants (27.8%) had negative feelings
regarding their psychiatrist. Participants stated that

they felt their psychiatrist was doing his/her job, yet
the psychiatrist would not listen to the participants'

concerns. Some examples of responses to this question
include, "He doesn't listen," "He prescribes medications,
get therapy elsewhere," and "I don't know■if he really

listens."
Many participants felt that they were .not given

enough time to talk to the psychiatrist. This could be
due to the overwhelming case load' that the doctors are
currently managing. The doctors do not have the time to

go over each detail in a client's life. Yet, if the
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client is to be involved in their own treatment plan, the
doctors must divide time equally for clients so they have
time to explain what they are feeling. Kerse et al.

(2004) noted that "trust" was significantly related to
adherence. Improving the relationship between client and

clinician can have long-term affects on medication

adherence (Kerse et al., 2004).

The researchers then asked the participants how they
expected their psychiatrist to treat them. Almost

one-half (40%) wanted to be treated "professionally" by
their psychiatrist. Being treated "respectfully" and

using active listening skills were each represented by 25
percent of the participants (i.e., 50% of total responses
when added together). Another 10 percent wanted their

psychiatrist to demonstrate compassion. Many participants
feel they are not being treated as they should. If one of

the precipitating factors in client adherence to a
psychotropic regime is the quality of the relationship
with their clinician, then we as a mental health field

are failing to create an adequate, therapeutic and

trusting working relationship with these clients.
Participants were also asked if it was their

decision alone to take medications. About 63 percent
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(62.5 %) stated "no," and only 37.5 percent of
respondents thought that it was their decision. The large
percentage of participants stating that it is not their

decision may suggest that many clients feel that they

must take psychotropics to receive services for their
mental illness, and they will take them even if the

psychotropics appear to do nothing in terms of managing
their symptoms.

Of the 62.5 percent who stated "no" to the above

question, 60 percent believe that the doctor makes the
decision to take medications, 20 percent believe that

society makes that decision, and another 20 percent
believe that they bear some of the decision making

responsibility. This finding is troublesome as
participants feel that it is not their choice to either

take the medications or refuse them for a different

treatment plan (i.e., alternative treatment plans that do

not involve psychotropics). This finding may result in
clients feeling disempowered, and perhaps even as if they

are subjects of social control, and thus less apt to

comply with their medication regimen.
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Self-medicating Behaviors
The researchers attempted to discover whether the
participants had, in the past, utilized illegal

substances instead of taking their prescribed
psychotropic medications. Over one-half (56.3%) stated
that they had never utilized substances instead of their

psychotropics. This is another question for which
responses may be influenced social desirability. Of the
43.7 percent that stated that they had used illegal drugs

instead of their psychotropics, over one third (38.6%) of

the participants stated that the reason was to reduce
symptoms. The other answers ranged from feel different

(23.1%), environment (7.6%), and boredom (7.6%). Another
23.1 percent of the responses were categorized as "other"

as the respondents stated concurrent usage of drugs and

psychotropics. Johnson, Brems, and Burke (2002) noted
that 45 percent of substance abuse clients also had a
mental disorder indicating the'difficulty of separating

these two issues.

The researchers have working relationships with most
of the participants in this study as interns at the

AB2034 program. The researchers believe that the

participants may have wanted to keep their drug use
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private so that they would not lose services of the
program. This seemed apparent in many answers to survey

questions. The researchers needed to address
confidentiality several times during interviews as
clients struggled with telling their whole story. For
example, when a participant was asked what type of

medications s/he was currently taking, s/he asked "Who is
going to see this research?" The researcher assured the

participant that s/he would riot be identified as there

were no names included in the study results. In fact, the
doctors would not know who had participated in the study.

Limitations

The first and foremost limitation of this study is

its sample size. Due to the nature of this exploratory

study, the researchers limited the- participants to fewer
than 20. The researchers conducted one-on-one interviews

with each participant. Before the interview could begin,

the participants were required to pass a mini-mental
status exam performed by the program manager. If the
study had been given unlimited time and resources, all

100 clients in the AB2034 would have been interviewed.
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Due to the limited size of the sample, generalizing the
findings to the rest of this population is difficult.

The second limitation concerns the nature of this
exploratory study. There are limitations in terms of the

participants self-reporting. In many cases participants
will not report honest answers to the researchers for
several different reasons. One, despite numerous

assurances of confidentiality, the respondents may have
been concerned that some of their responses could be

later traced back to them, and their continued
participation in the AB program would have been
j eopardized.

This aspect may have led at least some participants
to answering some questions, in a social desirable
fashion. Participants may also have been concerned with

telling everything to the researchers due to the

researchers and respondents having a current working
relationship. And, some participants may have been

concerned with the embarrassment, shame, and stigma
attached to reporting certain behaviors, such as illicit

drug use.
Another limitation to this study was the design of

the questionnaire. This study is unique as the
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researchers wanted to tap into the participants' reasons
for psychotropic adherence/nonadherence. The lack of a

standardized questionnaire led the researchers to create
the questionnaire based on their ideas gathered from
existing research. Once the interviews began, the

researchers identified several questions that they would

either change or eliminate altogether. Some questions

were designed to elicit a particular response, yet the
question was unfortunately designed to be answered with a
yes/no response. This limited the data collected on

several respondents. An example of this is the question,
"Can you tell me what was going on in your life at that

time?" Many respondents answered that question with a

"no".

The final limitation to this study was noted by the

researchers, in that all the participants were recruited
from the same agency. This fact makes generalizing the

findings to other similar agencies difficult, as well as

to the entire population of clients with SPMI.

Recommendations for Social Work
Practice, Policy and Research
The available research that is written on

adherence/nonadherence to psychotropic regimes is based
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solely on quantitative data collection and analysis. This

qualitative project solicited responses from the
participants' viewpoints, asking them exactly what they

felt instead of having them select their responses from a

list of answer options. This gave the participants the
opportunity to voice their concerns in their own words.
This study is unique in that the participants were

permitted to state anything that they saw necessary to
further explain their answers. The answers were written
verbatim during each interview. The use of a tape

recorder may have helped reduce the time of each
interview as the researcher had to ask the participants

to give them additional time to record their responses.
This may have altered the results, as the participants
may have lost their train of thought, however to what
degree we cannot be certain.

Clear explanations could have been useful to the
participants in terms of the guidelines for accepting

services from the AB2034 program. Many participants may
have altered their answers to cover up any undesirable

behaviors that could eliminate them from the program in
their perception (i.e., illegal drug use, nonadherence to

treatment plan, and negative thoughts about the program).
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The study would have been best performed if no one
working in the agency knew which respondents

participated, attempted to participate, or were asked

questions about the study. The study could have been
performed in the privacy of the participants' home,

utilizing personnel to perform the mini-mental status
exam that had no knowledge of the participant or history.
This may have helped the participants to answer questions

in a safer environment, as no one knew them or could
affect the services they receive from the program.
Another conclusion drawn from this study is that

clients must be better informed about their diagnosis and
medication regimes. This idea supports the psychosocial
model of rehabilitation. If a client understands what
they have been diagnosed with and how the psychotropics

affect their body, the client will have more insight into
their illness. Client insight provides for more effective

self-determination. If the doctor and case managers spent
more time educating the client about his/her illness,
this would conceivably produce a more informed consumer

and foster a more positive working relationship between

client and clinician, which is integral to a client's
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adherence to a treatment plan, which many times rely on

psychotropics.
The client would also have the requisite knowledge

to decide which medication they would like to try based
on more than just rumors from other clients in the
program. Perhaps then, clients may attain the type of
egalitarian relationship with their doctor that will

promote more equal decision making power, respect, and

client self-determination. This egalitarian relationship

is the key to recovery (Kerse et al., 2004) .
Our recommendations based on our findings are to
include more psychoeducational training in the following

areas: building more egalitarian clinician-client working
relationships, disseminating information and ensuring
clients' understanding of their diagnosis, mental

illness, symptoms, symptom management, with clinicians

striving to reduce the stigma associated with mental
illness, and better educate clients about their
medications, specifically how they work and why each they

need them, and exploring alternative treatments to

psychotropics with clients.
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Conclusions

The purpose of this study was to examine barriers to

psychotropic adherence/nonadherence from the client's
perspective. This study examined the similarities between

data collected utilizing quantitative measures and the
data collected using the qualitative measures of this

study. Interesting, the participants described many of

the same barriers to psychotropic adherence as the
current scholarly research. Participants described side
effects, insight, self medicating behaviors, and

relationship between client and clinician as the barriers
they face while attempting to be psychotropic adherent.
Each of these factors are important to future
studies, particularly from the client's perspective, as
the latest model of recovery includes the clients as the

experts into their own illness and recovery. The Mental
Health Services Act (MHSA) is currently changing the face
of mental health services to become more client and

family centered. This study was a first attempt at
starting the conversation about the need to create a more

egalitarian working relationship between clients and
clinicians to assist in the former's recovery.
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Additional studies should be conducted to replicate

the findings of this project and be informed by these
researchers' suggestions for an improved methodology.
When researchers asked the participants what has

worked and did not work for them in recovery, new
interventions can be created that can address the very

barriers that each client with SPMI faces each day on the

road to recovery.
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Survey
Instructions: (read aloud)
This study was designed to give you, the participant, an opportunity to share
your experiences with mental health services. I will read each question just as
it is written, I can re-read the question if you do not understand it the first time.
If you still do not understand the question, or you do not want to answer the
question, for any reason, I will go onto the next question. Please take your
time answering the questions. You may stop this interview at anytime. Are you
ready for me to begin?

1.

Are you currently taking psychiatric medications to address symptoms
related to a mental illness?
If yes,
a.
What type?
b.
Pills or a shot?

2.

Can you tell me why you take medication?
(a) Probing: How have medications helped you?

3.

Tell me the reasons why you do not like taking your medication.
(a) Probing: Have you talked to anyone about this?

4.

Can you remember a time when you decided not to take your
medications? If yes,
(a) Probing: Can you tell me what was going on in your life at that time?

5.

How would do you feel about your psychiatrist?
(a) Probing: How do you expect your psychiatrist to treat you?
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6.

Was there ever a time in your life when you used substance such as;
alcohol, cocaine, marijuana, methamphetamines, heroin, etc., instead of
your medication? If yes,

(a) Probing: Can you tell me why you decided to do illegal drugs instead
of taking your medication?
7.

Can you tell me some reasons you might not want to take medications?

8.

Thinking about the mental health services you have received: What
services do you believe have most improved your quality of life?

9.

What services do you believe would help people with mental illness have
a better life?

10.

Do you believe it is your decision alone, to take medication? Yes or No
(a) Who do you believe makes this decision?
(b) Probing: Can you tell me more about that?
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DEMOGRAPHICS
TODAY’S DATE:
ID#:
MARITAL STATUS:

(circle one)

1= Single/never married
2= Married
3= Separated
4= Divorced
5= Widowed
RACE: (circle one)

1= White/Caucasian
2= Black or African American
3= Hispanic or Latino
4= Asian
5= American Indian/Alaskan Native
6= Other

IN THE PAST 12 MONTHS HAVE
YOU BEEN/RECEIVED: (circle all that
apply)

1= Hospitalized for Psychiatric Care
2= Incarcerated (Jail or Prison)
3= Substance Detoxification
4= Substance Rehabilitation
(in-patient)
5= Substance Rehabilitation
(out-patient)
CURRENT DIAGNOSIS:
(Circle all that apply)

1=
2=
3=
4=
5=
6=
7=
8=

Schizophrenia
Schizoaffective Disorder
Bipolar Disorder
Major Depressive Disorder
Substance Abuse Disorder
Post-traumatic Stress Disorder
Borderline Personality Disorder
Other

GENDER: (circle one) Male/Female
AGE:
CURRENT EMPLOYMENT STATUS:
(circle one)

1= Unemployed
2= Part-time (1-24 hours/week)
3= Full-time (25+ hours/week)
CURRENT LIVING SITUATION:
(circle one)

1= Homeless
2= Hotel
3= Independent
4= with Family
5= Board and Care
6= Room and Board
7= Sober Living Facility
8= Other
HIGHEST GRADE OR LEVEL OF
SCHOOL
COMPLETED: (circle one)
1 = 8th Grade or Less
2= Some High School
3= High School Graduate or GED
4= Some College or 2-Year Degree
5= 4-Year Degree
6= More Than 4-Year College Degree
INCLUDING ALL MENTAL HEALTH
AGENCIES, HOW LONG HAVE YOU
BEEN RECEIVING MENTAL
HEALTH SERVICES:
(circle one)

1=
2=
3=
4=
5=
6=
7=
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Less than 2 year
2 - 5 years
5 - 7 years
7 -10 years
More than 10 years
I don’t know
other

APPENDIX B

TABLE OF RANDOM NUMBERS
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Table of Random Numbers

Each value was randomly selected, with an equal chance of choosing any
integer between 1 and 98.
Row#
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

A
93
97
52
14
75
30
87
57
65
70
21
32
36
81
58
42
30
16
84
58

B
43
60
24
75
74
42
42
70
49
46
62
12
37
79
97 :

33
24
19
57
73

C
22
74
47
8
10
60
93
46
79
48
71
73
61
96
86
5
21
96
33
17

D

E
86
80

43
70
■ 6
71
43
49 '2 :
87
33
20 ; 85 ■
11
63
87
54
37
.22
89
67
71
12
69 ' 77
63
10
73
55
95
,19
51
3
16
58
60
69
58
4

F
83
79
67
61
63 \
47

G
59 ■'
45
2
41
46 -

85
82
18
37
42
74
91
94
45
34 k ' S '<?
9
15

17
30
34
34
47
53
69
82

29
18
6
97
29
32
86
83

I
H
94
35
7
69
27
80
87
19
22
93
36
67
47
19
53
54
76 7 97
1
88
37
11
83
10
88 ? 81
37
91
29 • 86
2
35
36 .’••• 59
2
3
89
28 . .
98
91

J
36
59
65
22
98
69
74
7
47
31
39
59
96
14
81
41
50
19
6
36
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80

YOU ARE INVITED TO PARTICIPATE
IN A STUDY INTERVIEW

As a participant in this study, you would be asked to
complete a Mini, Mental Status Exam.
followed by a short- interview. . .

■Participation in this study is
voluntary and confidential,

‘

In appreciation of your time you will
receive $15' cash-.

' Your., participation would involve coming to
■ The MHA drop-in center in Santa Ana'
On January 27th for approximately one hour.'

For more information about this study, or to ■■
Volunteer for this study, please, . contact:

‘ ‘ '

Nicole Nanchy or -Michelle Green,.
Social Work Graduate Students.-.
or your PSC at (714) 668-8498.

. • ’

■

.'

This study has been approved by. the Institutional Review
Board for California State University San Bernardino
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Mini Mental Status Exam (MMSE)
ID#________________________ Date:__________________
MAXIMUM
SCORE

SCORE

(1 point per right answer)

ORIENTATION

5

Wbat is the? (year) (season) (date) (day) (month)

5

Where are we? (state) (county) (city) ( hospital) ( (floor)

3

Name 3 common objects (e.g. apple, table, penny). Take 1 second to pronounce
each word. The ask the patient to repeat all 3 words. Give one point for each correct
answer.

REGISTRATION

ATTENTION AND CALCULATION

5

Ask the patient to spell “WORLD” backwards. The score is the number of letters in
correct order (D_L_R_O_W_).

3

Ask the patient for the three objects repeated above. Give 1 point for each correct
answer. (Note: Recall cannot be tested if all 3 objects were not remembered during
registration.)

RECALL

LAUNGAGE

2

Show the patient a “pencil” and a “watch” and ask him/her to name them.

1

Ask patient to repeat the following: [ No its, ands or buts]

3

Ask patient to follow a 3-stage command:
[ take a paper in your right hand, fold it in hal£ and put it on the floorj
Ask the patient to read and obey the following:
•
Close your eyes.
•
Write a sentence
•
Copy the following design. oJ
x.
/
i

Maximum
Total Score
30

Total
Score
(
)

Mild:
Moderate:
Severe:

MMSE >21
MMSE 10-20
MMSE < 9

Based on this assessment, is this individual cognitively capable to participate in this
study? (circle one)
YES / NO
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Mini Mental Status Exam (MMSE)
ID#______________________________ Date:______________________________

This paper is to be used for MMSE participants to respond to written questions. Please attach this sheet
to MMSE test instrument.
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Informed Consent for Participation in the Interview

Title of Research: An Exploratory Study of Barriers to Psychotropic Adherence
from the Client’s Perspective.
Name of Researchers: Nicole Nanchy and Michelle Green, Social Work
Graduate Students
You are invited to participate in a research study exploring barriers to
treatment adherence. First, you will be asked to participate in a Mini Mental
Status Exam. Next, you may be asked to participate in an interview lasting
approximately one hour. Participation is this study is voluntary and
confidential. You are free to withdraw from this study or decline answering any
questions at anytime without being asked why you have made this decision.
There are no foreseen risks beyond those of everyday life. The benefit you
may receive for your participation in this study is the opportunity to share your
experiences with mental health services, specifically, your experience taking
psychotropic medication. Your involvement in this study will help identify
barriers to treatment, which may lead to better mental health practices. You
will receive a Visa gift certificate for $15 in return for your time and effort.

This study has been approved by the Institutional Review Board for California
State University, San Bernardino.

If you have any questions or concerns please contact research advisor,
Herbert Shon, Ph.D., L.C.S.W. at (909) 537-5532.
Please check the box below to indicate that you have read this informed
consent and choose to participate in this interview. By checking this box you
are also verifying that you are 18-years of age or older.

Please place a checkmark here □

Today’s Date: __________ _
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Debriefing Statement

Title of Research: An Exploratory Study of Barriers to Psychotropic Adherence
from the Client’s Perspective.
Name of Researchers: Nicole Nanchy and Michelle Green, Social Work
Graduate Students

We would like to take this time to thank you for your participation in this study.
You have participated in a research study that explored people’s opinions and
beliefs about psychiatric medications. You were asked to participate in a Mini
Mental Status Exam and a one-to-one interview. Participation is this study was
anonymous and confidential.
We ask all participants to avoid discussing the nature of this study with other
participants as it may influence their responses. A copy of the study results will
be provided and available to you through the Mental Health Association of
Orange County, AB2034 Program by September 15, 2006.

If you have any concerns about having participated in this research study,
contact Herbert Shon, Ph.D., L.C.S.W. at (909) 537-5532.
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DEFINITION OF TERMS

empowerment In social work practice, the process of helping individuals,
families, groups, and communities increase their personal,
socioeconomic, and political strength, and develop influence toward
improving their circumstances (Barker, 2003).
evidenced-based practice (EBP) The use of the best available scientific
knowledge derived from randomized controlled outcome studies, and
meta-analysis of existing outcome studies, as one basis for guiding
professional interventions and effective therapies, combined with
professional ethical standards, clinical judgment, and practice wisdom
(Barker, 2003).

macro practice Social work practice aimed at bringing about improvements
and changes in the general society. Such activities include some types
of political action, community organizations, public education
campaigning, and the administration of broad-based Social services
agencies or public welfare departments (Barker, 2003).
medical model An approach to helping people that is patterned after the
orientation used by many physicians. This includes looking at the
clients as an individual with an illness to be treated, giving relatively
less attention to factors in the clients environment, diagnosing the
condition with fairly specific labels, and treating the problems through
regular clinical appointments (Barker, 2003).

mental status exam mini A systematic evaluation of a patients level of
psychosocial, intellectual, and emotional functioning (Barker, 2003).
micro practice The term used by social workers to identify professional
activities that are designed to help solve the problems faced primarily
by individuals, families, and small groups. Usually micro practice
focuses on direct interventions on a case-by-case basis or in a clinical
setting (Barker, 2003). \
pharmacotherapy The administration of medications to help maximize the
physical or mental health potential of a patient. This includes educating
the patient about the need for the drug and its proper use, monitoring,
and taking efforts to modify the prescription as needed. Counseling
support are also important (Barker, 2003).
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DEFINITION OF TERMS

psychoeducation The process of teaching clients with a mental illness and
\ their family members about the nature Of the illness, including its
etiology, progression, consequences, prognosis, treatment, and
alternatives (Baker, 2003).
psychopharmacology The study and use of drugs to bring about changes in
behavior and personality (Barker, 2003).
psychosis Psychotic episode A serious and frequently incapacitating mental
disorder that may be of organic or psychological origin. These disorders
are characterized by some or all of the following symptoms: impaired
thinking and reasoning ability, perceptual distortions, inappropriate
emotional responses, inappropriate affect, regressive behavior, reduced
impulse control, impaired reality testing, ideas of reference,
hallucinations, and delusions,(Barker, 2003).

psychotropic Drugs used by psychiatrists to help their patients achieve
psychological or emotional changes (Barker, 2003). Classifications:
1. Antipsychotics (such as; Thorazine, Haldol, Prolixin).

2. Antidepressents (such as; Prozac, Elavil, Norpramin).
3. Antimanics (Lithium carbonate-that is, Eskalith, Lithane, or
Lithonate).

4. Antianxiety agents (such as; Valium, Ativan & various barbiturates).
(Barker, 2003).
rational emotive therapy A psychotherapeutic method based on the cognitive
theory of psychologist Albert Ellis, in which the client is encouraged to
make distinctions between what is objective fact in the environment and
the inaccurate, negative, and self-Jimiting interpretations made of one’s
own. behavior and life (Barker, 2003).
reality theory Psychosocial and behavioral intervention, developed by William
Glasser, that focuses on the clients behavior rather than the past.
Therapists encourage working out alternative solutions to problems.
They do not accept client excuses, rarely ask “why,” and place little
emphasis on taking case histories (Barker, 2003).
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Table 1
Gender

Valid

Male

Percent
37.5

Frequency
6

Female

Total

Valid Percent
37.5

Cumulative
Percent .
37.5

100.0

10

62.5

62.5

.16

100.0

100.0

Table 2
Age

Valid

24.00

Frequency
1

Percent
Valid Percent
6.3
6.3
6.3;
6.3

Cumulative
Percent
6.3

29.00

1

31.00

2

12.5

12:5

1
1

6.3
6.3

6.3

31.3

6.3

37.5

2
1

12.5
6.3

12.5
6.3

50.0
56.3

2
1
1

12.5
6.3
6.3

12.5
6.3

1
1

6.3
6.3

6.3
6.3
6.3

68.8
75.0
81.3

1

6.3’

6.3

16

100.0

100.0

32.00

.

36.00

44.00
45.00
46.00
47.00
50.00
51.00
59.00

61.00
Total

‘

12.5
25.0

.

87.5
93.8
100.0

Table 3
Race

Valid

White Caucasian
Black or African American
Other

Refused to answer
question.

Total

Frequency
8

Percent
50.0

Valid Percent
50.0

Cumulative
Percent
50.0

3

18.8

18.8

68.8

3

18.8

18.8

87.5

2

12.5

12.5

100.0

16

100.0

100.0
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Table 4
Marital Status

Valid

Percent
50.0

Frequency
8

Single/never married

Valid Percent
50.0

Cumulative
Percent
50.0

Separated

1

6.3

6.3

56.3

Divorced

6

37.5

37.5

93.8
100.0

Widowed

Total

1

6.3

6.3

16

100.0

100.0

Table 5
Employment Status

Valid

unemployed
Part-time
Total

Frequency
15
1'

Percent
93.8

Valid Percent
93.8

6.3
100.0 '

16

6.3

Cumulative
Percent
93.8
100.0

100.0

Table 6
Education

Valid

8th grade of less
Some High School
H.S. Graduate or GED
Some College or 2yr.
Degree
Total

Frequency
2

Percent
.. 12.5

Valid Percent
12.5

Cumulative
Percent
12.5

3
5

18.8
31.3

18.8
31.3

31.3
62.5

6

37.5

37.5

100.0

16

100.0

100.0
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Table 7
History

Valid

Hospitalized for Psych Tx

Frequency
2

Percent
12.5

Valid Percent
12.5

Cumulative
Percent
12.5

2

12.5

12.5

25.0

1

6.3

31.3

8

6.3
50.0

50.0

81.3

2

12.5

12.5 .

93.8

1.

6.3

6.3

100.0

100.0

100.0

Incarcerated
Substance Detox

'

None.
Psych hospitalization
and incarceration.
Incarceration and
substance detox.

Total

16

Table 8
Tx Duration

Valid

)

Cumulative
Percent
6.3

Frequency
1

Percent
6.3

4
2

25.0

25.0

31.3

5-7 years
7-10 years
More than 10 years

2
7

12.5
12.5

43.8
56.3

43.8

. 12.5
12.5
43.8

16

100.-0

100.0

Less than 2 yrs.
2- 5 years

Total

Valid Percent
6.3

100.0

Table 9
Housing

Valid

Frequency
3

Percent
18.8

Valid Percent
18.8

Cumulative
Percent
18.8

Independent

9

56.3

56.3

75.0

with Family

1

6.3

6.3

81.3

Sober Living Facility
Other

.2
1

■ 12.5
6.3

12.5
6.3

100.0

Total

16

100.0

100.0

Homeless

95

93.8

Table 10
Diagnosis

Valid

Schizophrenia

Frequency
5

Percent
31.3

Valid Percent
31.3

Cumulative
Percent
31.3

Schizoaffective Disorder

2

12.5

12.5

43.8

Bipolar Disorder

5

31.3

31.3

75.0

1

6.3

6.3

81.3

1

6.3

6.3

87.5

1

6.3

6.3

93.8

100.0

Major Depressive
Disorder
Schizoaffective, Bipolar,
Schizophrenia

Schizophrenia and Major
Depressive Disorder.

Bipolar, Schizoaffective
Total

1

6.3

6.3

16

100.0

100.0
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